What are the latest funding news in the longevity market? (May 2026)
Download our beautiful pitch about the longevity market
In our longevity market deck, you will find everything you need to understand the market
Longevity funding stayed active into May 2026, with recent rounds covering clinic infrastructure, diagnostics, therapeutics, and consumer healthspan platforms.
The most visible capital went to companies that could turn longevity science into regulated products, clinical workflows, or recurring consumer programs.
This makes the longevity market less of a single category and more of a connected stack across biology, care delivery, data, and prevention.
And if you want to better understand this new industry, you can download our pitch covering the longevity market.
Insights
- The 12 latest longevity market rounds totaled about $442.2M, but Function Health and Loyal alone represented roughly 90% of that capital.
- Clinic infrastructure is becoming investable, with Ultralight raising $9.3M for longevity EHR software and TMRW raising $7M to expand longevity clinics.
- Therapeutics remained the deepest science bucket, with Loyal, Aeovian, Junevity, and NewLimit together raising at least $210M across healthspan drug development.
- Biological age diagnostics kept attracting capital, as GlycanAge and Generation Lab raised money to make aging biomarkers more usable in preventive care.
- The market is splitting between high-touch clinical models and scalable software or diagnostics, which suggests investors are backing both delivery and discovery layers.
- Consumer longevity is still fundable when the model is clear, as Blueprint and L-Nutra both raised growth capital around protocolized healthspan products.
- Most valuations were not disclosed, but Function Health reported a $2.5B valuation, showing how large preventive healthspan platforms can become.
- The recent funding mix shows longevity investors are not only funding future anti-aging drugs, but also near-term tools that monetize today through clinics and memberships.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Summary table of the latest funding deals in the longevity market as of May 2026
We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.
We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.
We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.
You can also read our detailed analysis to understand how funding activity in the longevity market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the longevity market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Blueprint | 28 Oct 2025 | $60.0M | Growth equity | Consumer longevity platform |
| NewLimit | Oct 2025 | $45.0M | Undisclosed round | Longevity therapeutics & cellular rejuvenation |
| Generation Lab | Oct 2025 | $11.0M | Seed | Longevity diagnostics & biomarkers |
| Function Health | 19 Nov 2025 | $298.0M | Series B | Preventive longevity & healthspan platform |
| Junevity | 3 Dec 2025 | $10.0M | Seed extension | Longevity therapeutics & cellular reprogramming |
| Aeovian Pharmaceuticals | 16 Dec 2025 | $55.0M | Series B | Longevity therapeutics |
| Decode Age | 17 Dec 2025 | $1.7M | Pre-Series A | Consumer longevity diagnostics & supplements |
| GlycanAge | 18 Dec 2025 | $8.7M | Funding round | Longevity diagnostics & biomarkers |
| L-Nutra | Jan 2026 | $36.5M | Series D+ investment | Consumer & clinical longevity nutrition |
| Loyal | 11 Feb 2026 | $100.0M | Series C | Longevity therapeutics & canine healthspan |
| TMRW | 13 Mar 2026 | $7.0M | Seed | Longevity clinics & diagnostics |
| Ultralight | 13 Apr 2026 | $9.3M | Pre-seed & seed | B2B longevity clinic infrastructure |
All the latest funding deals during in the longevity market as of May 2026
Ultralight raised $9.3M in April 2026 for longevity clinic software.
When was it?
The deal was announced on 13 April 2026.
Who are they?
Ultralight builds EHR software made for longevity and personalized medicine clinics.
Geographical focus?
Ultralight appears focused on the US clinic market first, with software that can scale across longevity care providers.
Why do we include them in the longevity market?
Ultralight belongs in the longevity market because its product supports clinics that deliver healthspan and personalized longevity programs.
What is the company stage?
Ultralight is at an early product-market fit stage and plans to raise a Series A in 2027.
How much did they raise?
Ultralight raised $9.3M in this round.
What round is it?
The round combined pre-seed and seed funding.
Why did they raise?
Ultralight raised to build and scale clinic software for the growing longevity clinic market.
TMRW raised $7M in March 2026 to expand longevity clinics.
When was it?
The deal was announced on 13 March 2026.
Who are they?
TMRW is an Australian longevity membership clinic using biomarkers, epigenetic age testing, and clinical support.
Geographical focus?
TMRW is focused on Australia, with a clinic model that could later expand to other health-conscious urban markets.
Why do we include them in the longevity market?
TMRW fits the longevity market because the company sells clinical programs built around healthspan measurement and optimization.
What is the company stage?
TMRW is at an early product-market fit stage and is expanding its clinic footprint.
How much did they raise?
TMRW raised $7.0M in this round.
What round is it?
The round was a seed round.
Why did they raise?
TMRW raised to expand clinics and improve the patient experience.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Loyal raised $100M in February 2026 for canine longevity drugs.
When was it?
The deal was announced on 11 February 2026.
Who are they?
Loyal develops FDA-regulated medicines designed to extend healthy lifespan in dogs.
Geographical focus?
Loyal is primarily focused on the US pet therapeutics market, with a regulated model that could influence global animal healthspan care.
Why do we include them in the longevity market?
Loyal fits the longevity market because the company is developing therapeutics that directly target lifespan and healthspan biology.
What is the company stage?
Loyal is a clinical-stage company preparing for market readiness.
How much did they raise?
Loyal raised $100.0M in this round.
What round is it?
The round was a Series C.
Why did they raise?
Loyal raised to complete FDA requirements, scale the team and distribution, and prepare for launch.
L-Nutra secured $36.5M in January 2026 for longevity nutrition.
When was it?
The deal was announced in January 2026.
Who are they?
L-Nutra commercializes fasting-mimicking and medical nutrition programs linked to longevity science.
Geographical focus?
L-Nutra has a global expansion focus, with consumer and clinical nutrition products that can be sold across markets.
Why do we include them in the longevity market?
L-Nutra fits the longevity market because its products are explicitly positioned around longevity nutrition and medical nutrition therapies.
What is the company stage?
L-Nutra is a growth-stage company with existing products and global expansion plans.
How much did they raise?
L-Nutra secured $36.5M in this investment.
What round is it?
The investment was part of a Series D+ financing.
Why did they raise?
L-Nutra raised to accelerate global expansion of longevity and medical nutrition therapies.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
GlycanAge raised $8.7M in December 2025 for biological age diagnostics.
When was it?
The deal was announced on 18 December 2025.
Who are they?
GlycanAge offers glycan-based biological age diagnostics for preventive and healthy-aging care.
Geographical focus?
GlycanAge has a global clinician-access focus, with roots in the UK and Europe.
Why do we include them in the longevity market?
GlycanAge belongs in the longevity market because biological age testing is used to measure and manage healthspan interventions.
What is the company stage?
GlycanAge is in early growth, with a focus on clinical development and clinician access.
How much did they raise?
GlycanAge raised about $8.7M in this round.
What round is it?
The round was described as a funding round.
Why did they raise?
GlycanAge raised to accelerate clinical development and expand clinician access worldwide.
Decode Age raised $1.7M in December 2025 for longevity science.
When was it?
The deal was announced on 17 December 2025.
Who are they?
Decode Age uses biomarkers, gut microbiome analysis, and supplements to target aging pathways.
Geographical focus?
Decode Age is focused on India, with a model that could expand as consumer longevity diagnostics grow.
Why do we include them in the longevity market?
Decode Age fits the longevity market because the company combines diagnostics and supplements around explicit aging biology.
What is the company stage?
Decode Age is in early product-market fit and expansion mode.
How much did they raise?
Decode Age raised $1.7M in this round.
What round is it?
The round was a Pre-Series A.
Why did they raise?
Decode Age raised to expand biomarker discovery, multi-omics research, microbiome research, and analytics infrastructure.
In our longevity market deck, we identify pain points entrepreneurs should prioritize
Aeovian Pharmaceuticals raised $55M in December 2025 for mTORC1 therapeutics.
When was it?
The deal was announced on 16 December 2025.
Who are they?
Aeovian Pharmaceuticals develops selective mTORC1 inhibitors tied to cellular metabolic quality control and age-related biology.
Geographical focus?
Aeovian Pharmaceuticals is a US biotech with global relevance because its programs address regulated drug markets.
Why do we include them in the longevity market?
Aeovian Pharmaceuticals belongs in the longevity market because mTOR biology is a core pathway in age-related disease and healthspan research.
What is the company stage?
Aeovian Pharmaceuticals is a clinical-stage biotech company.
How much did they raise?
Aeovian Pharmaceuticals raised $55.0M in this round.
What round is it?
The round was a Series B.
Why did they raise?
Aeovian Pharmaceuticals raised to fund completion of Phase 2 proof-of-concept work for AV078.
Junevity added $10M in December 2025 for cell reprogramming with siRNA.
When was it?
The deal was announced on 3 December 2025.
Who are they?
Junevity develops siRNA cell-reprogramming therapeutics aimed at metabolism, lifespan, and healthspan.
Geographical focus?
Junevity is a US biotech with a global therapeutic opportunity if its programs reach clinical and commercial stages.
Why do we include them in the longevity market?
Junevity belongs in the longevity market because its therapeutics are built around cellular reprogramming and healthspan improvement.
What is the company stage?
Junevity is preclinical and moving toward first-in-human studies.
How much did they raise?
Junevity raised $10.0M in this seed extension.
What round is it?
The round was a seed extension, expanding total seed funding to $20M.
Why did they raise?
Junevity raised to advance JUN_01 through IND-enabling work and initial clinical studies.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Function Health raised $298M in November 2025 for preventive health.
When was it?
The deal was announced on 19 November 2025.
Who are they?
Function Health combines biomarker testing, imaging, and AI medical intelligence for preventive health.
Geographical focus?
Function Health is focused mainly on the US market, with a scalable digital and diagnostics-led model.
Why do we include them in the longevity market?
Function Health fits the longevity market because its platform is built around prevention, biomarkers, and long-term health optimization.
What is the company stage?
Function Health is a growth-stage company.
How much did they raise?
Function Health raised $298.0M in this round.
What round is it?
The round was a Series B.
Why did they raise?
Function Health raised to launch medical intelligence and scale its preventive health platform.
Blueprint raised $60M in October 2025 for its consumer longevity platform.
When was it?
The deal was announced on 28 October 2025.
Who are they?
Blueprint turns Bryan Johnson's longevity protocol into diagnostics, nutrition, prescriptions, skincare, and AI coaching.
Geographical focus?
Blueprint has a global consumer focus through digital products and shippable longevity programs.
Why do we include them in the longevity market?
Blueprint fits the longevity market because the company sells a structured consumer program for healthspan and long-term optimization.
What is the company stage?
Blueprint is a growth-stage consumer longevity company.
How much did they raise?
Blueprint raised $60.0M in this round.
What round is it?
The round was described as growth equity.
Why did they raise?
Blueprint raised to turn a personal longevity protocol into a broader precision-health platform.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Generation Lab raised $11M in October 2025 for organ-level biological age testing.
When was it?
The deal was announced in October 2025.
Who are they?
Generation Lab measures biological aging across organ systems through its SystemAge diagnostic platform.
Geographical focus?
Generation Lab is focused on the US market first, with a diagnostics platform that could support broader preventive care use cases.
Why do we include them in the longevity market?
Generation Lab belongs in the longevity market because biological age diagnostics help users and clinicians track aging and healthspan.
What is the company stage?
Generation Lab is at an early product-market fit stage.
How much did they raise?
Generation Lab raised $11.0M in this round.
What round is it?
The round was a seed round.
Why did they raise?
Generation Lab raised to scale SystemAge and expand biological-age diagnostics.
NewLimit raised $45M in October 2025 for epigenetic reprogramming medicines.
When was it?
The deal was announced in October 2025.
Who are they?
NewLimit develops epigenetic reprogramming medicines designed to restore youthful cell function.
Geographical focus?
NewLimit is a US biotech with a global therapeutic opportunity if its medicines reach approval.
Why do we include them in the longevity market?
NewLimit fits the longevity market because cellular rejuvenation and epigenetic reprogramming are core longevity therapeutics themes.
What is the company stage?
NewLimit is a clinical-enabling biotech growth company.
How much did they raise?
NewLimit raised $45.0M in this round.
What round is it?
The round amount was disclosed, but the round type was not disclosed.
Why did they raise?
NewLimit raised to continue developing therapeutic programs that aim to reverse age-related cellular changes.
Related blog posts
- How strong is fundraising in the longevity market right now?
- The most recent news in the longevity market
- How large is the longevity market in reality?
- The evolution of funding activity in the longevity market
- The main fundraising trends in the longevity market
- All the recent funding deals in the longevity market
- The startups that have raised the most funding in the longevity market
- The most highly valued startups in the longevity market
